Abstract
Background HTLV-1/2 and HIV likely share the same transmission routes and thus in Europe HTLV occurs mainly among IDUs, interests in clinical implications of HTLV-1/2 coinfection on HIV disease progression have risen. So far the available evidence suggests a protective role of HTLV-2 and adverse effect of HTLV-1 on HIV infection. In Europe, the overall prevalence of HTLV infection is up to 18% among IDUs and less than 1% among blood donors. However, there is no data regarding the overall prevalence of HTLV-1/2 in Eastern-European IDU population where the HIV epidemic mainly lies. We aimed to determine the prevalence of HTLV among IDUs in Estonia and compare it with the rate in healthy volunteers.
Highlights
HTLV-1/2 and HIV likely share the same transmission routes and in Europe HTLV occurs mainly among intravenous drug users (IDUs), interests in clinical implications of HTLV-1/2 coinfection on HIV disease progression have risen
There is no data regarding the overall prevalence of HTLV-1/2 in Eastern-European IDU population where the HIV epidemic mainly lies
We aimed to determine the prevalence of HTLV among IDUs in Estonia and compare it with the rate in healthy volunteers
Summary
Ene-Ly Jõgeda1*, Radko Avi, Merit Pauskar, Eveli Kallas, Tõnis Karki, Don Des Jarlais, Anneli Uusküla, Irja Lutsar, Kristi Huik. From 17th International Conference on Human Retroviruses: HTLV and Related Viruses Trois Ilets, Martinique. From 17th International Conference on Human Retroviruses: HTLV and Related Viruses Trois Ilets, Martinique. 18-21 June 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
